Schedule 13D ownership disclosure
ESSA PHARMA INC
Common Stock · CUSIP: 29668H708
Event date: 2025-04-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SOLEUS CAPITAL MASTER FUND, L.P.Reported CIK 0001812275
Shares: 2,262,026.00 · Class: 5.1%
- SOLEUS CAPITAL, LLC
Shares: 2,262,026.00 · Class: 5.1%
- SOLEUS CAPITAL GROUP, LLC
Shares: 2,262,026.00 · Class: 5.1%
- SOLEUS CAPITAL MANAGEMENT, L.P.
Shares: 2,262,026.00 · Class: 5.1%
- SOLEUS GP, LLC
Shares: 2,262,026.00 · Class: 5.1%
- GUY LEVY
Shares: 2,262,026.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-034772
- Form type
- SCHEDULE 13D/A
- Filer
- ESSA Pharma Inc.
- CIK
- CIK 1633932
- Filed
- Apr 23, 2025
- Reporting period
- Apr 23, 2025
- Description
- Schedule 13D beneficial ownership